MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Early Phase 1
Recruiting
Conditions
Relapsed/refractory Lymphoma
Relapsed/Refractory Leukemia
Interventions
Biological: anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2025-01-03
Last Posted Date
2025-01-03
Lead Sponsor
Affiliated Hospital of Nantong University
Target Recruit Count
9
Registration Number
NCT06756321
Locations
🇨🇳

Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Phase 2
Not yet recruiting
Conditions
Aplastic Anemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Transplantation
Procedure: Computed Tomography
Drug: Cyclosporine
Drug: Fludarabine
Drug: Granulocyte Colony-Stimulating Factor
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Ruxolitinib
Drug: Sirolimus
Radiation: Total-Body Irradiation
First Posted Date
2024-12-31
Last Posted Date
2024-12-31
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT06752694
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

US Zamto-cel Autoimmune Diseases

Phase 1
Not yet recruiting
Conditions
Lupus Nephritis
Systemic Lupus Erythematosus
Systemic Sclerosis (SSc)
Diffuse Cutaneous Systemic Sclerosis
Interventions
Biological: zamtocabtagene autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2024-11-27
Last Posted Date
2024-11-27
Lead Sponsor
Miltenyi Biomedicine GmbH
Target Recruit Count
48
Registration Number
NCT06708845

UF-KURE-BCMA CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma

Phase 1
Not yet recruiting
Conditions
Multiple Myeloma
Multiple Myeloma in Relapse
Multiple Myeloma, Refractory
Interventions
Biological: UF-KURE-BCMA CAR T-cells
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
David Wald
Target Recruit Count
12
Registration Number
NCT06698744
Locations
🇺🇸

University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland, Ohio, United States

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Phase 1
Not yet recruiting
Conditions
Lymphoma, T-Cell
Interventions
First Posted Date
2024-11-21
Last Posted Date
2024-11-25
Lead Sponsor
GC Cell Corporation
Target Recruit Count
48
Registration Number
NCT06699771
Locations
🇰🇷

Seoul National University Hosptial, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Early Phase 1
Recruiting
Conditions
B-Cell Acute Lymphoblastic Leukemia, Adult
Interventions
Biological: QH10304-BAL-01
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2024-11-20
Last Posted Date
2024-11-20
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
18
Registration Number
NCT06696833
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, China, Jiangsu, China

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase 2
Not yet recruiting
Conditions
Gastrointestinal Carcinoma
Pancreatic Cancer
Hepatocellular Cancer
Cholangiocarcinoma
Duodenal Cancer
Colorectal Cancer
Small Bowel Cancer
Metastatic Cancers
Interventions
First Posted Date
2024-11-15
Last Posted Date
2025-01-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT06690281
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical Study of ARD103 CAR-T Therapy for Patients with R/R AML or MDS

Phase 1
Not yet recruiting
Conditions
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
MDS (Myelodysplastic Syndrome)
Interventions
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
ARCE Therapeutics, Inc.
Target Recruit Count
49
Registration Number
NCT06680752

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Phase 2
Not yet recruiting
Conditions
Acute Myelogenous Leukemia
Acute Lymphatic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Myelodysplastic Syndrome Other
Chronic Myelomonocytic Leukemia
Lymphoma
Interventions
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Thiotepa
Radiation: Total Body Irradiation
Biological: Double Umbilical Cord Transplant
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Abatacept
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
Leland Metheny
Target Recruit Count
20
Registration Number
NCT06680661
Locations
🇺🇸

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Phase 1
Not yet recruiting
Conditions
Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Non-Active Secondary Progressive Multiple Sclerosis
Non-Active SPMS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Demyelinating Diseases
Immune System Diseases
Interventions
First Posted Date
2024-11-07
Last Posted Date
2024-11-07
Lead Sponsor
Indapta Therapeutics, INC.
Target Recruit Count
34
Registration Number
NCT06677710
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States

🇺🇸

Stanford University, Stanford, California, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath